TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07176650: Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Trea

Sponsor: Shanghai Henlius Biotech · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 246 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT07176650 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07176650 Rescue Dossier →